Tests YH32364 in adults with advanced solid tumors that overexpress EGFR
Tests the drug YH32364 in adults with advanced cancer that overexpresses EGFR.
Key facts
- Who runs it
- Yuhan Corporation
- Where
- Seoul, South KoreaSee the 4 sites
- Trial code
- Registry title
- Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 80 people, planned
- Started
- 12 Jun 2025
- Expected to end
- Dec 2029
- Type of study
- Interventional
- Treatments tested
- YH32364
- Record updated
- 10 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with locally advanced or metastatic cancer that shows too much EGFR (EGFR overexpression) and that did not respond to, or could not be treated with, standard therapy.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Locally advanced or metastatic solid tumor with EGFR overexpression (IHC3+ or IHC2+) that is refractory or intolerable on all available standard therapy and cannot be cured by local therapy. Tumor types include head and neck squamous cell carcinoma, squamous non-small cell lung cancer, esophageal squamous cell carcinoma, biliary tract cancer, cervical cancer, vulvar cancer, urothelial cancer and other squamous cell carcinomas. The expansion cohort 1 is for head and neck squamous cell carcinoma other than nasopharyngeal carcinoma.
- Earlier treatment
- Must have had all available standard therapy without success or been unable to tolerate it. Cannot have had systemic steroid therapy, a 4-1BB/CD137-modulating agent, immunotherapy, biological therapies, targeted small molecules, hormonal therapies, radiation therapy or cytotoxic chemotherapy (as listed in the exclusion criteria). Cannot have used a live vaccine within 4 weeks.
- Biomarker or test result
- EGFR overexpression confirmed in the tumor by pathology (IHC3+ or IHC2+).
Main reasons for not taking part
- Uncontrolled central nervous system metastases, spinal cord compression or carcinomatous meningitis
- Class II, III or IV heart failure, or a heart attack or other acute coronary event within the past 24 weeks
- Current or past interstitial lung disease or pneumonitis that needed steroids
- HIV infection, or active chronic hepatitis B or C
- Autoimmune disease that needed systemic treatment
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Must sign an informed consent form (ICF) prior to any study specific procedures
- ECOG performance status 0 or 1
- Estimated life expectancy of at least 3 months
- A woman must not be breastfeeding
- Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements; [Dose Escalation Only] Locally advanced or metastatic EGFR overexpressing solid tumor* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy
- One of the following pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+) tumors
- Head and neck squamous cell carcinoma (HNSCC)
- Non-small cell lung cancer (NSCLC): squamous cell carcinoma (SqCC)
- Esophageal squamous cell carcinoma (ESCC)
- Biliary tract cancer (BTC)
- Uterine cervical cancer
- Vulvar cancer
- Urothelial cancer
- Squamous cell carcinoma of other origin of tumor (e.g., skin squamous cell tumor); [Dose Expansion Only] Cohort 1: Pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+), locally advanced or metastatic HNSCC other than nasopharyngeal carcinoma (NPC)* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy
Who cannot take part
- Active chronic hepatitis B or chronic hepatitis C; [Prior/Concomitant Therapy]
- Have received systemic steroid therapy
- Previous treatment with a 4-1BB/CD137-modulating agent
- Have used a live vaccine within 4 weeks
- Have received treatment with immunotherapy, biological therapies, targeted small molecules, or hormonal therapies
- Have received radiation therapy
- Have received cytotoxic chemotherapy
- Have history of a second primary cancer with the exception of; curatively treated non-melanomatous skin cancer; curatively treated cervical or breast carcinoma in situ, or; other malignancy with no known active disease present and no treatment administered during the last 2 years
- Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA)
- Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks
- Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis
- Have autoimmune disease that has required systemic treatment
- Infection with human immunodeficiency virus (HIV)
- Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and/or carcinomatous meningitis
This trial is currently available in South Korea.
- Korea University Anam HospitalSeoul, South KoreaContact: Clinical Operation Team 1Taking people
- Samsung Medical CenterSeoul, South KoreaContact: Clinical Operation Team 1Taking people
- Seoul National University HospitalSeoul, South KoreaContact: Clinical Operation Team 1Taking people
- Severance hospitalSeoul, South KoreaContact: Clinical Operation Team 1Taking people
About the trial
What the trial wants to find out
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
The group in the trial
- YH32364Treatment being tested
Dose Escalation Part: Dose Escalation part is designed to assess the safety and tolerability of YH32364 and to identify the Maximum Tolerated dose (MTD) and/or two dose levels for recommended dose (RD) selection. Dose Expansion Part: Dose Expansion part will consist of multiple cohorts by cancer types. Cohort 1 will be initiated to determine the RD after completion of Part 1. The RD will be determined among two dose levels investigated in Cohort 1 based on the totality of available data including PK, biomarkers, dose-response, safety, and efficacy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors
- Plain-language title
- Tests YH32364 in adults with advanced solid tumors that overexpress EGFRGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 June 2026